At AstraZeneca, we’re pioneering new computational pathology approaches, combining digital pathology and big data with cutting-edge artificial intelligence to enhance patient selection and enable more personalised treatments, with the ultimate goal of improving patient outcomes.
Evinova’s Digital Solution will be used by Study Sites to monitor patients enrolled in Quantum Leap’s I-SPY-2.2 at risk of developing interstitial lung disease
Genomics offers scientists an extraordinary ability to explore human health by decoding insights within our DNA to develop medicines that can target the root causes of disease. But to truly understand the complexity of human disease, researchers are advancing beyond the genome. Enter multi-omics—the integration of genomics with other biological data such as proteomics, transcriptomics, and metabolomics.
Chronic diseases impact the lives of more than two billion people worldwide, reducing quality of life and increasing mortality, and presenting complex challenges for healthcare systems, communities and society.
With ageing populations, the rising burden of chronic disease and the impacts of climate change on health, health systems are struggling to meet people’s health needs.
A Bari sono stati presentati i risultati dell’edizione 2024 dello studio realizzato da The European House - Ambrosetti sul valore creato dal Gruppo AstraZeneca in Italia attraverso la ricerca e il progresso tecnologico. Risultati che fanno del nostro Paese un “luogo” strategico per AstraZeneca e Alexion, destinato a diventare sempre più centrale nei prossimi anni.
Approximately 850 million people worldwide are living with chronic kidney disease (CKD), a progressive and potentially fatal condition. Yet, the majority remain undiagnosed and untreated.
Preferences
Would you like to share some personal information with us so we can improve your experience on Researchalize.org?
